Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 CAD | +0.70% | -6.49% | -19.55% |
Apr. 11 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
Apr. 11 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
Sales 2024 * | 857K 623K | Sales 2025 * | 6.68M 4.85M | Capitalization | 108M 78.4M |
---|---|---|---|---|---|
Net income 2024 * | -36M -26.17M | Net income 2025 * | -40M -29.08M | EV / Sales 2024 * | 126 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 16.2 x |
P/E ratio 2024 * |
-3.22
x | P/E ratio 2025 * |
-3.25
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.84% |
Latest transcript on Oncolytics Biotech Inc.
1 day | -0.69% | ||
1 week | -10.06% | ||
Current month | -1.38% | ||
1 month | +0.70% | ||
3 months | -9.49% | ||
6 months | -37.55% | ||
Current year | -20.11% |
Managers | Title | Age | Since |
---|---|---|---|
Matthew Coffey
CEO | Chief Executive Officer | - | 11-05-10 |
Kirk Look
DFI | Director of Finance/CFO | - | 03-03-31 |
Thomas Heineman
CTO | Chief Tech/Sci/R&D Officer | - | 20-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Rigby
BRD | Director/Board Member | 56 | 22-09-06 |
Patricia Andrews
BRD | Director/Board Member | 66 | Jan. 08 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 15-06-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.44 | +0.70% | 23 577 |
24-04-18 | 1.43 | -0.69% | 23,151 |
24-04-17 | 1.44 | -2.04% | 31,075 |
24-04-16 | 1.47 | +0.68% | 19,284 |
24-04-15 | 1.46 | -5.19% | 87,736 |
Delayed Quote Toronto S.E., April 18, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.11% | 78.44M | |
-1.82% | 41.35B | |
+42.21% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- ONC Stock